SCHEMBL27218848

SCHEMBL27218848

CC(C)(C)c1cc(O)nc(SCCCc2nc(-c3ccc(Cl)cc3)no2)n1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 3/20 0.52
▸ LMNA P02545 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ HDAC2 Q92769 2/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ TSHR P16473 3/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ NOTUM Q6P988 2/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ ERCC1 P07992 1/20 0.43
▸ ERCC4 Q92889 1/20 0.43
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27218812 0.90 SIRT2 (0.52) SIRT2LMNANPC1RAB9AALDH1A1
SCHEMBL31494429 0.90 ALDH1A1 (0.47) LMNANPC1RAB9AALDH1A1HDAC2
SCHEMBL27218808 0.85 RAB9A (0.50) LMNANPC1RAB9AALDH1A1HDAC2
SCHEMBL27218682 0.82 S1PR1 (0.45) SIRT2LMNANPC1RAB9AALDH1A1
SCHEMBL27218694 0.80 HDAC1 (0.49) SIRT2LMNANPC1RAB9AALDH1A1
SCHEMBL27218707 0.78 SMN1; SMN2 (0.48) SIRT2LMNANPC1RAB9AALDH1A1
SCHEMBL27218814 0.76 LMNA (0.55) SIRT2LMNANPC1RAB9AALDH1A1
SCHEMBL27218893 0.74 S1PR1 (0.47) SIRT2LMNANPC1RAB9AALDH1A1
SCHEMBL29808217 0.73 L3MBTL1 (0.47) LMNANPC1RAB9AALDH1A1HDAC2
SCHEMBL27218860 0.72 RAB9A (0.47) LMNANPC1RAB9AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 SIRT2 1845/4885LMNA 3526/4885NPC1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback